)
Lupin Limited announced today that it has received final approval for its Rifabutin capsules from the US food and Drugs Administration(USFDA) to market the generic version of Mycobutin capsules, used to prevent a disease condition in patients with advanced HIV infection.
The company's American subsidiary, Lupin Pharmaceuticals Inc, would begin marketing the product shortly, accoding to a press release. The Mycobutin capsules had annual US sales of $ 18.6 million, it said.
